Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EDSA 
Edesa Biotech Inc (EDSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.64% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.83M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 0.08 | 52 Weeks Range 1.28 - 4.49 | Updated Date 12/25/2025 |
52 Weeks Range 1.28 - 4.49 | Updated Date 12/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-12-15 | When - | Estimate -0.2667 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.02% | Return on Equity (TTM) -99.57% |
Valuation
Trailing PE - | Forward PE 0.17 | Enterprise Value 9816516 | Price to Sales(TTM) 120477.93 |
Enterprise Value 9816516 | Price to Sales(TTM) 120477.93 | ||
Enterprise Value to Revenue 128525.38 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 8333823 | Shares Floating 4800115 |
Shares Outstanding 8333823 | Shares Floating 4800115 | ||
Percent Insiders 16.8 | Percent Institutions 34.52 |
Upturn AI SWOT
Edesa Biotech Inc
Company Overview
History and Background
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company. It was founded in 2014 with a focus on developing innovative therapies for inflammatory and immune-related diseases. Key milestones include advancing its lead drug candidates through clinical trials and establishing strategic partnerships.
Core Business Areas
- Inflammatory and Immune-Related Diseases: Edesa Biotech focuses on developing novel treatments for a range of inflammatory and immune-related conditions, aiming to address unmet medical needs in areas such as gastroenterology, dermatology, and oncology.
Leadership and Structure
Edesa Biotech Inc. is led by a management team with extensive experience in drug development and the biopharmaceutical industry. The company operates with a lean structure, prioritizing its clinical development programs.
Top Products and Market Share
Key Offerings
- EDSA-930: A novel small molecule inhibitor targeting chronic spontaneous urticaria (CSU). Competitors include drugs like Xolair (omalizumab) and antihistamines. Market share data for this specific compound is not yet available as it is in clinical development.
- EDSA-801: A monoclonal antibody targeting cytokines implicated in various inflammatory diseases. Competitors include a wide range of biologic therapies for autoimmune and inflammatory conditions. Market share data for this specific compound is not yet available as it is in clinical development.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on inflammatory and immune-related diseases, is characterized by rapid innovation, significant R&D investment, and a high degree of competition. The market is driven by the increasing prevalence of chronic diseases and the demand for more effective and targeted therapies.
Positioning
Edesa Biotech Inc. is positioned as a clinical-stage biopharmaceutical company aiming to develop differentiated therapies for underserved patient populations within the inflammatory and immune-related disease space. Its competitive advantage lies in its novel drug candidates and focused development strategy.
Total Addressable Market (TAM)
The total addressable market for inflammatory and immune-related diseases is substantial, encompassing billions of dollars globally. Edesa Biotech Inc. is positioning itself to capture a share of this market with its specific drug candidates targeting niche indications within these broad disease areas.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential for differentiated efficacy and safety profiles.
- Experienced management team with a track record in drug development.
- Focus on significant unmet medical needs in inflammatory and immune-related diseases.
- Lean operational structure allowing for efficient resource allocation.
Weaknesses
- Clinical-stage company with no approved products, leading to high R&D costs and no current revenue generation.
- Reliance on external funding for continued research and development.
- Potential for clinical trial failures and regulatory hurdles.
- Limited brand recognition compared to larger, established pharmaceutical companies.
Opportunities
- Advancing drug candidates through clinical trials towards regulatory approval.
- Potential for strategic partnerships and licensing agreements with larger pharmaceutical companies.
- Growing demand for innovative treatments for chronic inflammatory and autoimmune diseases.
- Expansion into new therapeutic areas or indications for existing drug candidates.
Threats
- Intense competition from established pharmaceutical companies and other biotech firms.
- Stringent regulatory requirements for drug approval.
- Unforeseen clinical trial outcomes or adverse events.
- Challenges in securing sufficient funding for late-stage clinical development and commercialization.
- Changes in healthcare policy and reimbursement landscapes.
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Amgen Inc. (AMGN)
- Eli Lilly and Company (LLY)
- Bristol Myers Squibb Company (BMY)
- Regeneron Pharmaceuticals, Inc. (REGN)
Competitive Landscape
Edesa Biotech Inc. faces a highly competitive landscape populated by large, well-established pharmaceutical companies with significant R&D budgets, extensive product portfolios, and established market presence. Edesa's advantage lies in its focused approach to specific unmet needs and potentially innovative mechanisms of action for its drug candidates. However, it lacks the financial resources and market penetration of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historically, Edesa Biotech Inc.'s growth has been characterized by the progression of its pipeline through preclinical and early clinical development stages, alongside fundraising efforts to support these activities.
Future Projections: Future growth projections for Edesa Biotech Inc. are largely dependent on the successful outcomes of its ongoing clinical trials and subsequent regulatory approvals. Analyst estimates, if available, would typically focus on the potential market penetration of its lead candidates.
Recent Initiatives: Recent initiatives likely involve advancing its lead drug candidates (e.g., EDSA-930 and EDSA-801) through their respective clinical trial phases, potentially initiating new trials, and engaging in business development activities to support its pipeline.
Summary
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company with promising drug candidates in the inflammatory and immune-related disease space. Its strengths lie in its innovative pipeline and experienced team. However, it faces significant challenges due to its early-stage development, reliance on funding, and intense competition from larger players. The company needs to successfully navigate clinical trials and regulatory pathways while securing adequate financing to realize its potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations materials (if publicly available)
- SEC filings (10-K, 10-Q, 8-K)
- Reputable financial data providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share estimates are subject to change and may vary depending on the source. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edesa Biotech Inc
Exchange NASDAQ | Headquaters Markham, ON, Canada | ||
IPO Launch date 2015-11-05 | CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.edesabiotech.com |
Full time employees 17 | Website https://www.edesabiotech.com | ||
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.